MLND - Millendo Therapeutics commences in-human clinical trial for MLE-301

Millendo Therapeutics (MLND) announces dosing of the first subject in a Phase 1 clinical trial evaluating the safety, pharmacokinetics and preliminary efficacy of MLE-301. The first-in-human trial is designed to evaluate the safety and tolerability of MLE-301.“We are pleased to advance MLE-301 into clinical development, prioritizing our resources on this valuable asset and leveraging Millendo’s expertise in the NK3R category," said Julia C. Owens, President and CEO.Press Release

For further details see:

Millendo Therapeutics commences in-human clinical trial for MLE-301